Use of Maraviroc-,Raltegravir-,and Etravirine-Containing Regimens in Treatment-Experienced Patients: A Case-Series Study

Abstract

The development of newer agents such as raltegravir, etravirine and maraviroc has improved the perspective of viral load suppression. However, there is not enough data regarding their use together. In this study, we describe nine patients who were triple-class experienced and were on a salvage regimen consisting of a combination of raltegravir, etravirine, and maraviroc. Our results showed that this regimen is safe with no major side effect and has good virological efficacy with two-thirds of the patients achieving an undetectable viral load by 24 weeks.

Keywords

HAART HIV infectious disease

References

UK Collaborative Group on HIV Drug Resistance ; UK CHIC Study Group. Long-term probability of detecting drug-resistant HIV in Treatment-naïve patients initiating combination antiretroviral therapy. Clin Infect Dis. 2010;50(9):1275-1285.

Gardner EM , Hullsiek KH , et al. Antiretroviral medication adherence and class-specific resistance in a large prospective clinical trial. AIDS. 2010;24(2):395-493.

Hawkins C. , Murphy RL Management of antiretroviral failure and resistance in developing countries . Curr Opinion HIV AIDS. 2009;4(6):538-544.

Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. December 1, 2009; 1-161. http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed June 24, 2010.

FDA Press Release. FDA Approves Novel Antiretroviral Drug. 2007. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm108960.htm. Accessed June 24, 2010.

FDA Press Release. FDA Approves New HIV Drug: Raltegravir Tablets Used in Combination with Other Antiretroviral Agents. 2007. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm109008.htm. Accessed June 24, 2010.

FDA Press Release. FDA Approves New HIV Drug After Priority Review: Etravirine tablets used in combination with other antiretroviral agents. 2008. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2008/ucm116841.htm . Accessed June 24, 2010.

Nozza S. , Visco F. , Soria A. , et al. Excellent short-term CD4 recovery with a PI- and NRTI-sparing regimen in triple-class failure HIV-infected patients: raltegravir, maraviroc, etravirine. J Int AIDS Soc. 2008;11(1):P45.